Tevabon caps #28 and tabs #4

Tevabon instruction for use

You can buy Tevabon capsules on this page

Composition

Tablets: alendronic acid, microcrystalline cellulose, magnesium stearate, croscarmellose sodium.
Capsules: alfacalcidol, citric acid, α-tocopherol, propyl gallate, peanut oil, ethanol, titanium dioxide, glycerol, gelatin.

Form of issue

A set of tablets and capsules:
    white round tablets, flat;
    capsules are gelatinous, oval in white.
In a blister of aluminum foil, 1 tablet and 7 capsules in a cardboard bundle No. 2, 4, 12 blisters.

pharmachologic effect

Regulating calcium-phosphorus metabolism, inhibiting resorption of bones.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

The action of the drug is determined by the active substances that make up its composition.
Alendronic acid
It refers to bisphosphonates, does not directly influence the formation of new bone tissue, it inhibits osteoclastic bone resorption. Alendronic acid has tropicity to the hydroxyapatite of bone, and, accordingly, accumulates in the zones of its active resorption. The effect is due to the stimulation of the process of apoptosis of osteoclasts. When receiving alendronic acid, bone mineralization increases and its qualitative characteristics are normalized.
Alfacalcidol
The precursor of the pharmacologically active metabolite of vitamin D3, takes part in the regulation of calcium-phosphorus metabolism. It increases the absorption of calcium and phosphorus in the intestine, increases their reabsorption in the kidneys, reduces the concentration of parathyroid hormone in the blood, normalizes the calcium balance in the syndrome of calcium malabsorption.
Influencing the processes of bone resorption and synthesis, alfacalcidol increases the mineral content in bone tissue and its elasticity by strengthening the process of bone matrix protein synthesis, growth factors and bone morphogenetic proteins. With the use of alfacalcidol, the strength of the bones of the skeleton increases, a physiologically normal histological structure of the bones is formed.
Both active substances mutually increase the effects of each other, which ensures the formation and growth of a physiologically normal bone structure. Thanks to the synergistic effect of these substances, it is possible to reduce the risk of hypercalciuria, hypocalcaemia and hypercalcemia, which reduces the risk of fractures, increases muscle strength and the rate of muscular reaction.

Pharmacokinetics

Alendronic acid
Bioavailability at the level of 0,6%. After oral administration at a therapeutic dose, the concentration of alendronic acid in the blood is lower than the existing limit of detection. Binding to blood proteins is about 78%. Distributed initially in soft tissues, and then redistributed into the bone, where it is fixed. Biotransformation is not exposed, is excreted through the kidneys unchanged.
Alfacalcidol
Alfacalcidol is rapidly absorbed from the digestive tract. After a single dose of Cmax is achieved after 10 hours. Bioavailability is about 100%. In the body, it is converted to calcitriol by hydroxylation. Output is approximately equal to the ratio of kidney and liver, half-life about 35 hours.

Indications for use

Osteoporosis in the period of postmenopause. Osteoporosis, which developed as a result of the SCS.

Contraindications

High sensitivity to active substances of the drug, condition, esophageal stricture, hypocalcemia / hypercalcemia, pregnancy, kidney disease, hemodialysis, hypervitaminosis D, childhood, lactation.
Take with caution should be with exacerbation of diseases of the gastrointestinal tract, atherosclerosis, with hypoparathyroidism, active form of pulmonary tuberculosis, malabsorption of calcium, leukemia, hypovitaminosis D, nephrolithiasis, CHF.

Side effects

When taking alendronic acid: general malaise, nausea, vomiting, gastritis, esophagitis, constipation / diarrhea, erosion of the esophagus mucosa, dyspepsia, abdominal pain, dysphagia, flatulence, stomach ulcer, bone pain, myalgia, muscle cramps, hypocalcemia, usually associated with predisposing conditions, hypophosphatemia, headache, scleritis, local allergic reactions, fever.
When taking alfacalcidol: hypercalcemia, heartburn, vomiting, fatigue, weakness, drowsiness, dizziness, pain in muscles, joints, allergic reactions.

Tevabon, instructions for use (Method and dosage)

The composition of the drug includes two dosage forms: capsules of alfacalcidol and tablets of alendronic acid.
Alendronovaya acid - take inside 1 tablet once a week for 30 minutes before breakfast or taking other drugs.
Tablets can not be chewed. Wash with plain water. Before the morning rise from bed or before bedtime, you can not take tablets. The patient should be in a vertical position for at least 30 minutes after taking the tablet.
Alfacalcidol - take 1 capsule swallowing whole and squeezed water 1 time / day daily in the evening.

Overdose

With the intake of alendronic acid in doses exceeding the recommended diarrhea, heartburn, hypophosphatemia, hypocalcemia, ulceration of the gastrointestinal tract, esophagitis.
In case of an overdose of Alfacalcidol, nausea, metallic taste in the mouth, fatigue, headache, bone pain, myalgia, increased blood pressure, weight loss, dry mouth, constipation, diarrhea, anorexia, skin itching, drowsiness, dizziness, general weakness, confusion.

Interaction

When the drug is taken together with food additives, drinks (including mineral water) and food containing calcium, there is a risk of disrupting the absorption of alendronic acid.
Preparations of SCS increase the side effect of alendronic acid on the gastrointestinal mucosa. Simultaneous reception of alfacalcidol with cardiac glycosides increases the risk of arrhythmia. Absorption of alfacalcidol is reduced by its simultaneous intake with mineral oil, antacids, colestipol, colestyramine, sucralfate, LS, albumin-based.
Simultaneous reception of alfacalcidol with thiazide diuretics, calcium preparations can cause hypercalcemia. It is not recommended that joint use of alfacalcidol with other drugs that contain vitamin D is associated with the risk of developing hypercalcemia. In postmenopausal women, the efficacy of alfacalcidol can be enhanced by the use of estrogen.

Storage conditions

In a dry place at a temperature of no higher than 25 ° C.
Shelf life - 36 months.

Reviews of Tevabon

Reviews about the drug among patients are favorable. "... I suffer from osteoporosis. Have appointed a medicine Tevabon almost half a year ago. The condition improved, the pain in the thoracic spine and hip decreased. " According to the doctors, taking the drug helps to increase BMD in places of increased stress, reducing pain and the frequency of bone fractures in osteoporosis.